https://www.prognyx.com/blog/j-j-s-tecvayli-talvey-phase-3-cuts-myeloma-progression-risk-as-early-as-second-lPrognyxen2026-11-11J J's TECVAYLI-TALVEY Phase 3 cuts myeloma progression risk as early as second line https://www.prognyx.com/blog/immunitybio-s-anktiva-meets-primary-endpoint-in-bcg-naive-bladder-cancer-trialPrognyxen2026-11-10ImmunityBio's ANKTIVA meets primary endpoint in BCG-naive bladder cancer trial https://www.prognyx.com/blog/j-j-reports-73-psa-response-for-pasritamig-jnj-9401-bispecific-prostate-comboPrognyxen2026-11-09J J reports 73% PSA response for pasritamig + JNJ-9401 bispecific prostate combo